Cargando…
Immune checkpoint analysis in ear cancer
BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626725/ https://www.ncbi.nlm.nih.gov/pubmed/37932810 http://dx.doi.org/10.1186/s13005-023-00395-w |
_version_ | 1785131396958781440 |
---|---|
author | Klein, M. Polgart, E. Hallermann, C. Schulze, H. J. Hölzle, F. Wermker, K. |
author_facet | Klein, M. Polgart, E. Hallermann, C. Schulze, H. J. Hölzle, F. Wermker, K. |
author_sort | Klein, M. |
collection | PubMed |
description | BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers. METHODS: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death). RESULTS: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients. CONCLUSION: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives. |
format | Online Article Text |
id | pubmed-10626725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106267252023-11-07 Immune checkpoint analysis in ear cancer Klein, M. Polgart, E. Hallermann, C. Schulze, H. J. Hölzle, F. Wermker, K. Head Face Med Research BACKGROUND: Among cutaneous squamous cell carcinomas, the ear (ecSCC) is one of the most common sites. Loco regional lymph node metastasis is found in six to eleven percent of cases, corresponding to increased metastasis compared to other sites. The aim of this study was to test the markers PD-L1, PD-1, CD4, CD8, and FoxP3 for suitability as prognostic predictive markers. METHODS: Sixty-four patients with ecSCC were included in this study. The expression of immunohistochemical markers (PD-L1, PD-1, CD4, CD8, FOXP3) was correlated with retrospective clinic pathological parameters (lymph node metastasis, distant metastasis, lymph node metastasis during follow-up, disease progression, disease-specific death). RESULTS: There was a correlation between increased disease specific death and a weak Foxp3 (p = 0.003) or reduced CD8 (p = 0.04). A PD-L1 expression > 1% was found in 39.1% of patients. CONCLUSION: The investigated markers (CD4, CD8, FoxP3, PD-1, PD-L1) seem overall rather inappropriate for prognostic evaluation in ecSCC. Only the correlation of disease specific death with CD8 or FoxP3 seems to be worth testing in larger collectives. BioMed Central 2023-11-06 /pmc/articles/PMC10626725/ /pubmed/37932810 http://dx.doi.org/10.1186/s13005-023-00395-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Klein, M. Polgart, E. Hallermann, C. Schulze, H. J. Hölzle, F. Wermker, K. Immune checkpoint analysis in ear cancer |
title | Immune checkpoint analysis in ear cancer |
title_full | Immune checkpoint analysis in ear cancer |
title_fullStr | Immune checkpoint analysis in ear cancer |
title_full_unstemmed | Immune checkpoint analysis in ear cancer |
title_short | Immune checkpoint analysis in ear cancer |
title_sort | immune checkpoint analysis in ear cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626725/ https://www.ncbi.nlm.nih.gov/pubmed/37932810 http://dx.doi.org/10.1186/s13005-023-00395-w |
work_keys_str_mv | AT kleinm immunecheckpointanalysisinearcancer AT polgarte immunecheckpointanalysisinearcancer AT hallermannc immunecheckpointanalysisinearcancer AT schulzehj immunecheckpointanalysisinearcancer AT holzlef immunecheckpointanalysisinearcancer AT wermkerk immunecheckpointanalysisinearcancer |